在2020年与羟基氯喹相关的不良药物反应

（健康日） - 根据2018年和2019年，与2018年和2019年，与羟基氯喹和氯喹相关的不良药物反应（ADRS）的数量与2018年和2019年在线上发表的一份研究函。内科。

Pharm.d.d，Pharm.，Pharm.，来自法国的格勒诺布尔Alpes大学医院，同事量化了与2018年和2019年的Covid-19大流行的开始以来与羟氯喹和氯喹的数量和类型的变化。

A total of 21,305 reports of 152,201 suspected ADRs concerning chloroquine and hydroxychloroquine were extracted from the U.S. Food and Drug Administration Adverse Event Reporting System database from Jan. 1, 2018, to Sept. 30, 2020. The researchers found that in 2020, the number of reported ADRs for chloroquine and hydroxychloroquine more than doubled (11,493 and 89,607, respectively) compared with the same months in 2018 (4,681 and 25,035, respectively) and 2019 (5,131 and 37,559, respectively). In 2020, the most represented countries were Canada, the United States, France, Spain, and Italy. Overall, 97.1 percent of the ADRs reported in 2020 were considered serious compared with 73.4 and 84.8 percent in 2018 and 2019, respectively. Similarly, 5.1 percent of reported cases in 2020 were fatal compared with 3.1 and 1.9 percent in 2018 and 2019, respectively.

“报告与氯喹相关的ADR的显着增加羟氯喹作者写道，在SARS-COV-2在大流行引起对广泛使用这些药物的潜在危害的危害令人担忧。

一位作者披露了财务关系制药业。

---

---

版权所有©2020.健康天。版权所有。